companiesCompany
SOFIE Biosciences
SOFIE Biosciences is a US radiopharmacy network running two phase 3 trials of the FAP PET tracer [18F]FAPI-74 in pancreatic and gastro-oesophageal cancer.
First patients dosed in the FAPI-GO (gastro-oesophageal, December 2025) and pancreatic (February 2026) phase 3 trials; seven radiopharmacies cleared to manufacture [18F]FAPI-74 with 12-hour shelf-life distribution planned in 2026. FAPI chemistry originated in Heidelberg.